Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ponsegromab vs placebo with first-line chemotherapy in metastatic pancreatic ductal adenocarcinoma with cachexia
CTR20260151Phase 3Active
- Sponsor
- Pfizer
- Start
- Mar 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of ponsegromab in pancreatic adenocarcinoma (PDAC), cancer anorexia-cachexia syndrome (CACS), sponsored by Pfizer. Started Mar 2026; status: active.
02
Drugs
ponsegromab
03
Conditions
pancreatic adenocarcinoma (PDAC)cancer anorexia-cachexia syndrome (CACS)
Beyond the preview
Go deeper on CTR20260151.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260151.